Cisplatin for Small Cell Lung Carcinoma

Phase-Based Progress Estimates
UPMC Hillman Cancer Center, Pittsburgh, PA
Small Cell Lung Carcinoma+2 More
Cisplatin - Drug
All Sexes
What conditions do you have?

Study Summary

This is trial studying the safety of adaptive stereotactic body radiotherapy (SBRT) combined with durvalumab immunotherapy, platinum chemotherapy, and etoposide chemotherapy in platinum refractory extensive stage small cell lung cancer (SCLC).

Eligible Conditions

  • Small Cell Lung Carcinoma
  • Extensive-stage Small-cell Lung Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Small Cell Lung Carcinoma

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: Up to 2.5 years

Year 5
Functional Assessment of Cancer Therapy-Lung (FACT-L)
Up to 2.5 years
Incidence of treatment-related adverse events (AEs)
Objective Response Rate (ORR)

Trial Safety

Safety Progress

1 of 3

Other trials for Small Cell Lung Carcinoma

Trial Design

1 Treatment Group

Single Treatment Arm
1 of 1
Experimental Treatment

50 Total Participants · 1 Treatment Group

Primary Treatment: Cisplatin · No Placebo Group · Phase 1

Single Treatment ArmExperimental Group · 5 Interventions: Etoposide Injection, Durvalumab 50 MG/1 ML Intravenous Solution, Stereotactic Body Radiotherapy, Cisplatin, Carboplatin · Intervention Types: Drug, Drug, Device, Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Stereotactic Body Radiotherapy
Completed Phase 2
Completed Phase 3
Completed Phase 3

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 2.5 years
Closest Location: UPMC Hillman Cancer Center · Pittsburgh, PA
Photo of UPMC Hillman Cancer Center  1Photo of UPMC Hillman Cancer Center  2Photo of UPMC Hillman Cancer Center  3
2007First Recorded Clinical Trial
7 TrialsResearching Small Cell Lung Carcinoma
63 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have no cancer or only a small amount of cancer.
You have a body weight of more than 30 kg.
You have a hemoglobin level of 10.0 g/dL or higher.
The criterion is that serum bilirubin is ≤1.5 x institutional upper limit of normal (ULN).

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.